Newsroom

テキサス州ザ・ウッドランズ--(BUSINESS WIRE)--（ビジネスワイヤ） -- パーマ・パイプ・インターナショナル・ホールディングス（NASDAQ：PPIH）は、2026年1月31日に終了した第4四半期および2025年度の財務業績を発表しました。 「2026年1月31日に終了した3か月間の売上高は5,510万ドルとなり、前年同期の4,500万ドルに比べて1,010万ドル（22.4%）増加しました。増収は、中東および北米の両地域で販売数量が増加したことによるものです。売上総利益は1,730万ドルとなり、前年の1,520万ドルから210万ドル増加しました。これは事業活動の拡大を反映したものです。販売費および一般管理費は970万ドルから1,030万ドルへと小幅に増加しました。主因は人件費の増加で、一部は賞与関連費用の減少により相殺されました。同社の実効税率（ETR）は12.3%となり、前年同期の32.1%から低下しました。これは各課税管轄における製品ミックスの影響を反映したものです。その結果、普通株主に帰属する純利益は490万ドルとなり、2024年度第4四半期の180万ドルに比べ...

STAMFORD, CT--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded...

ORANGE, Calif.--(BUSINESS WIRE)--My Mountain Mover, the leading provider of Medical Virtual Assistants for healthcare practices across the United States, proudly announces its official expansion into the dental industry, designed to meet the unique demands of dental practices nationwide. As staffing challenges and administrative workloads continue to grow in dental clinics, practices are looking for more efficient ways to scale without increasing in-house costs. MMM’s dental offering is designe...

AUSTIN, Texas--(BUSINESS WIRE)--Please replace the release dated April 9, 2026 with the following corrected version due to multiple revisions. The updated release reads: TERRADEPTH'S ABSOLUTE OCEAN CLEARED SELECTION PROCESS AND PLACED IN NIWC ATLANTIC RCC HOPPER Placement in the RCC Hopper could enable direct prototype awards without further competition, accelerating Navy adoption for unmanned undersea operations Terradepth, a venture-backed maritime technology company delivering the Ocean Oper...

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ:ATRA) investors of the May 22, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors a...

SAN JOSÉ, Calif.--(BUSINESS WIRE)--Power Integrations (Nasdaq: POWI) today announced that on April 15, 2026 (the Grant Date), it granted a total of 89 restricted stock units (RSUs) to one new employee who began employment with Power Integrations in April 2026. This inducement grant was granted pursuant to Power Integrations’ Amended and Restated 2025 Inducement Award Plan. One-fourth (1/4th) of the RSUs will vest on each of the first four anniversaries of the Grant Date, subject to the recipien...

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Propanc Biopharma Inc. (NASDAQ: PPCB) resulting from allegations that Propanc may have issued materially misleading business information to the investing public. So what: If you purchased Propanc securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangeme...

ELKHART, Ind.--(BUSINESS WIRE)--LCI Industries (NYSE: LCII) today confirmed that it is in discussions with Patrick Industries, Inc. (NASDAQ: PATK) regarding a possible merger of equals. These discussions are ongoing, and there can be no assurances that such discussions will result in a transaction or on what terms any transaction may occur. LCI Industries does not intend to comment further unless and until it determines further disclosure is appropriate. About LCI Industries LCI Industries (NYS...

荷兰奈梅亨--(BUSINESS WIRE)--(美国商业资讯)-- 独立生物制药公司Byondis B.V.专注于为癌症患者开发创新型靶向治疗药物。公司宣布，将于即日起至4月22日在美国加利福尼亚州圣地亚哥举行的2026年美国癌症研究协会（AACR）年会上，通过壁报展示形式集中呈现其具有同类首创优势的抗叶酸及膦酸类抗体偶联药物（ADC）技术平台。 Byondis首席科学官Wim Dokter博士表示：“我们在AACR年会上展示的研究成果，充分彰显了公司两大前沿ADC技术平台在弥补当前癌症治疗手段关键不足方面的潜力。我们同类首创的抗叶酸连接子-药物平台，基于已获临床验证的生物学机制，采用正交作用机制设计，旨在应对现有ADC疗法中可能出现的获得性耐药问题，从而具备覆盖不同治疗阶段的应用前景。与此同时，我们的膦酸连接子-药物平台通过提供互补性的作用机制，有望为患者带来新的治疗选择，包括对免疫治疗反应不佳的人群。这两大技术平台充分体现了公司致力于提供突破性解决方案、推动新一代癌症治疗发展的使命。” 抗叶酸抗体偶联药物（ADC）：具备清晰差异化作用机制的靶向治疗新型连接子-药物平台（摘要编号：...

NIJMEGEN, Países Baixos--(BUSINESS WIRE)--A Byondis B.V., empresa biofarmacêutica independente que desenvolve medicamentos direcionados inovadores para pacientes com câncer, apresentará suas plataformas tecnológicas pioneiras de conjugados de anticorpos e fármacos (ADC), antifolatos e fosfonatos, em sessões de pôsteres na Reunião Anual de 2026 da Sociedade Americana de Pesquisa do Câncer (AACR), em San Diego, Califórnia, até o dia 22 de abril. Wim Dokter, PhD, diretor científico da Byondis, dis...